|Table of Contents|

Association between CYP2D6 gene polymorphism and gefitinib adverse events in patients with NSCLC

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2021 02
Page:
248-253
Research Field:
Publishing date:

Info

Title:
Association between CYP2D6 gene polymorphism and gefitinib adverse events in patients with NSCLC
Author(s):
CHEN Lijuan; YU Tingting; SHAN Li; HAN Zhigang
Department of Oncologic Medicine,Affiliated Tumor Hospital of Xinjiang Medical University,Xinjiang Urumqi 830000,China.
Keywords:
NSCLC; gefitinib; CYP2D6; liver damage; rash
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2021.02.014
Abstract:
Objective:To explore the relationship between the occurrence of adverse reactions in the metabolism of oral gefitinib and the polymorphism of CYP2D6 gene.Methods:180 patients with NSCLC diagnosed in pathology department at Affiliated Tumor Hospital of Xinjiang Medical University from Jan.2016 to Dec.2018 were collected.The ARMS method was used to detect patients with EGFR19del or 21L858R sensitive mutations.During the follow-up,patients were divided into liver damage group and non-liver damage group,rash group and non-rash group according to the occurrence of adverse reactions,and peripheral blood was collected.Polymerase chain reaction (PCR)-restriction fragment length polymorphism (RFLP) was used to detect the rs1065852 genotype of CYP2D6 gene in the above patients.The risk factors for the treatment of liver damage and rash occurs in gefitinib were explored by the test of χ2.Results:The genotype,tumor stage and gene mutation type of rs1065852 of CYP2D6 gene in patients with non-small cell lung cancer were related to liver damage caused by gefitinib,while the genotype of rs1065852 of CYP2D6 gene and tumor stage were related to the occurrence of rash,which was of guiding significance for clinical medication.Conclusion:Patients who oral gefitinib tablets with advanced non-small cell lung cancer,rs1065852 polymorphism of CYP2D6 can predict liver function and the possibility of skin rash.

References:

［1］ 李娟,裘福荣.CYP2D6基因多态性对临床常用药物的作用［J］.中国现代药物应用,2019,13(16):229-232. LI J,QIU FR.The effect of CYP2D6 gene polymorphism on common clinical drugs［J］.Chinese Jurnal of Modern Drug Application,2019,13(16):229-232.
［2］ SUZUMURA T,KIMURA T,KUDOH S,et al.Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer［J］.BMC Cancer,2012,12(1):568.
［3］ SCHMIDT KT,CHAU CH,PRICE DK,et al.Precision oncology medicine:The clinical relevance of patient-specific biomarkers used to optimize cancer treatment［J］.J Clin Pharmacol,2016,56(12):1484-1499.
［4］ WELLMANN R,BORDEN BA,DANAHEY K,et al.Analyzing the clinical actionability of germline pharmacogenomic findings in oncology［J］.Cancer,2018,124(14):3052-3065.
［5］ FANG P,ZHENG X,HE J,et al.Functional characterization of wild-type and 24 CYP2D6 allelic variants on gefitinib metabolism in vitro［J］.Drug Des Devel Ther,2017,11:1283-1290.
［6］ WANG C,CHEN F,LIU Y,et al.Genetic association of drug response to erlotinib in chinese advanced non-small cell lung cancer patients［J］.Frontiers in Pharmacology,2018,9：360.
［7］ MCKILLOP D,MCCORMICK AD,MILLAR A,et al.Cytochrome P450-dependent metabolism of gefitinib［J］.Xenobiotica,2005,35(1):39-50.
［8］ ALFIERI RR,GALETTI M,TRAMONTI S,et al.Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines［J］.Molecular Cancer,2011,10(1):143.
［9］ EHMANN F,CANEVA L,PAPALUCA M.European medicines agency initiatives and perspectives on pharmacogenomics［J］.British Journal of Clinical Pharmacology,2014,77(4):612-617.
［10］ ZHANG H,LI Q,ZHU X,et al.Association of variability and pharmacogenomics with bioequivalence of gefitinib in healthy male subjects［J］.Frontiers in Pharmacology,2018,9:849.
［11］ XU ZY,LI JL.Comparative review of drug-drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer［J］.OncoTargets and Therapy,2019,12:5467-5484.
［12］ 田利萍,邹莹,吴景竹.精神分裂症患者CYP2D6基因多态性与利培酮疗效的相关性［J］.临床精神医学杂志,2018,28(02):98-100. TIAN LP,ZOU Y,WU JZ.Correlation between CYP2D6 gene polymorphism and risperidone efficacy in patients with schizophrenia［J］.Journal of Clinical Psychiatry,2018,28(02):98-100.
［13］ 伍筱玫,丁选胜.用于非小细胞肺癌治疗的第三代EGFR-TKIs研究进展［J］.药学进展,2016,40(11):826-832. WU XM,DING XS.Research progress of EGFR-TKI in the third generation for the treatment of non-small cell lung cancer［J］.Progress in Pharmaceutical Science,2016,40(11):826-832.
［14］ 陈艳波,孔德嘉,张金锋,等.乳腺癌患者CYP2D6基因多态性与他莫昔芬代谢相关性研究［J］.实用肿瘤学杂志,2019,33 (02):110-114. CHEN YB,KONG DJ,ZHANG JF,et al.Research on the correlation between CYP2D6 gene polymorphism and tamoxifen metabolism in breast cancer patients［J］.Practical Oncology Journal,2019,33(02):110-114.
［15］ ZHU QQ,WANG C,CHEN YY,et al.Impaired liver function implied shorter progression free survival for EGFR tyrosine kinase inhibitors［J］.Asian Pacific Journal of Cancer Prevention,2018,19(8):2177-2181.
［16］ THUM T,ERPENBECK VJ,MOELLER J,et al.Expression of xenobiotic metabolizing enzymes in different lung compartments of smokers and nonsmokers［J］.Environmental Health Perspectives,2006,114(11):1655-1661.
［17］ VOGEL WH,JENNIFER P.Management strategies for adverse events associated with EGFR TKIs in non-small cell lung cancer［J］.J Adv Pract Oncol,2016,7(7):723-735.

Memo

Memo:
新疆维吾尔自治区自然科学基金资助项目(编号：2017D01C381)
Last Update: 1900-01-01